BPA for livmarli

Active Awarded Last action

Contract number
36E79722A0020
Awardee
Awarding agency
Task orders
0

Award facts

Opportunity
  • VA797P12Q0002 Solicitation number
Last date to order 90% complete
IDV ceiling
$1,125,000.00
Award type
Single award
Who can order
Only the awarding agency
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price

Award details come from SAM.gov/FPDS.

About this IDV

This Blanket Purchase Agreement, awarded to Mirum Pharmaceuticals, Inc. on May 3, 2022, provides the National Acquisition Center (a civilian federal agency) with access to Livmarli, a pharmaceutical product used to treat Alagille syndrome, a rare genetic disorder affecting bile flow. The contract, valued at $1,125,000, operates as a single-award, unrestricted competition vehicle under the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The ultimate completion date of May 2, 2027 reflects the extended performance period necessary to support ongoing federal healthcare requirements, with the award representing the fourth option year exercise of the underlying Blanket Purchase Agreement 36E79722A0020. As the sole awardee, Mirum Pharmaceuticals is positioned to deliver this specialized orphan drug directly to federal healthcare agencies, including the U.S. Department of Veterans Affairs and associated Veterans Integrated Service Networks that serve eligible veteran populations.

Mirum Pharmaceuticals' federal contract portfolio demonstrates focused capability in the rare disease pharmaceutical sector, with this Blanket Purchase Agreement complementing the company's existing multiple-award and interim contracts under the same GSA schedule. The contract structure enables federal agencies to place task orders and purchase orders against the established ceiling value without additional competitive solicitation, streamlining procurement processes for this critical therapeutic agent. The absence of set-aside designations confirms the procurement was competed among all qualified vendors, reflecting confidence in Mirum's competitive positioning within the specialized pharmaceutical market. Through this Blanket Purchase Agreement, federal healthcare agencies can efficiently access Livmarli to support patients with Alagille syndrome, fulfilling the government's mission to deliver innovative therapeutic solutions to the beneficiary populations served.

Transactions

Action Obligated Date
Exercise an Option P00012 · Exercise option year 4 - BPA 36E79722A0020 $0
Supplemental Agreement for work within scope P00011 · Modification to incorporate 1 NDC addition $0
Supplemental Agreement for work within scope P00010 · 2026 public law pricing updates. $0
Supplemental Agreement for work within scope P00009 · This modification is issued to incorporate the addition of 2 cholbam ndcs and 4 livmarli ndcs on BPA 36E79722A0020. $0
Supplemental Agreement for work within scope P00007 · Product addition - livmarli $0
Exercise an Option P00008 · Exercise option year 3 on BPA 36E79722A0020. $0
Supplemental Agreement for work within scope P00006 · 2025 PL price update $0
Supplemental Agreement for work within scope P00005 · Modification to incorporate the product addition of 2 cholbam ndcs to BPA 36E79722A0020. $0
Exercise an Option P00004 · Exercise option year 2 on BPA 36E79722A0020 $0
Supplemental Agreement for work within scope P00003 · 2024 public law pricing updates $0
Exercise an Option P00002 · Exercise option year 1 on BPA 36E79722A0020 $0
Supplemental Agreement for work within scope P00001 · 2023 public law pricing updates $0
Original award $0
Show all 13

Quick answers

Who was awarded contract 36E79722A0020?

36E79722A0020 was awarded to Mirum Pharmaceuticals, Inc. by National Acquisition Center (Headquarters) on May 3, 2022.

How much is contract 36E79722A0020 worth?

36E79722A0020's own ceiling is $1,125,000.

Who can order from contract 36E79722A0020?

36E79722A0020 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.

Is contract 36E79722A0020 under another contract?

Yes. 36E79722A0020 is a blanket purchase agreement under 36F79722D0112, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36E79722A0020 competed?

The extent of competition for 36E79722A0020 was full and open competition. The government received 1 offer.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV